Aligos Therapeutics (ALGS)
NASDAQ:ALGS
Total Valuation
Aligos Therapeutics has a market cap or net worth of $41.21M. The enterprise value is $28.05M.
Market Cap$41.21M
Enterprise Value$28.05M
Share Statistics
Aligos Therapeutics has 5,387,807 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,387,807
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aligos Therapeutics’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -123.88%.
Return on Equity (ROE)-0.45
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-123.88%
Return on Capital Employed (ROCE)-1.31
Revenue Per Employee31.23K
Profits Per Employee-345.61K
Employee Count70
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aligos Therapeutics is ―. Aligos Therapeutics’s PEG ratio is 0.04.
PE Ratio―
PS Ratio42.14
PB Ratio1.72
Price to Fair Value1.72
Price to FCF-1.11
Price to Operating Cash Flow-0.84
PEG Ratio0.04
Income Statement
In the last 12 months, Aligos Therapeutics had revenue of 2.19M and earned -24.19M in profits. Earnings per share was -2.45.
Revenue2.19M
Gross Profit1.26M
Operating Income-87.98M
Pretax Income-23.88M
Net Income-24.19M
EBITDA-87.06M
Earnings Per Share (EPS)-2.45
Cash Flow
In the last 12 months, operating cash flow was -82.50M and capital expenditures -437.00K, giving a free cash flow of -82.94M billion.
Operating Cash Flow-82.50M
Free Cash Flow-82.94M
Free Cash Flow per Share-15.39
Dividends & Yields
Aligos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change-19.27%
50-Day Moving Average7.33
200-Day Moving Average8.69
Relative Strength Index (RSI)42.37
Average Volume (3m)86.97K
Important Dates
Aligos Therapeutics upcoming earnings date is May 12, 2026, After Close (Confirmed).
Last Earnings DateMar 5, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Aligos Therapeutics as a current ratio of 3.90, with Debt / Equity ratio of 9.80%
Current Ratio3.90
Quick Ratio3.90
Debt to Market Cap0.00
Net Debt to EBITDA0.15
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aligos Therapeutics has paid 314.00K in taxes.
Income Tax314.00K
Effective Tax Rate-0.01
Enterprise Valuation
Aligos Therapeutics EV to EBITDA ratio is -0.91, with an EV/FCF ratio of -0.95.
EV to Sales36.17
EV to EBITDA-0.91
EV to Free Cash Flow-0.95
EV to Operating Cash Flow-0.96
Balance Sheet
Aligos Therapeutics has $77.95M in cash and marketable securities with $5.25M in debt, giving a net cash position of $72.70M billion.
Cash & Marketable Securities$77.95M
Total Debt$5.25M
Net Cash$72.70M
Net Cash Per Share$13.49
Tangible Book Value Per Share$5.42
Margins
Gross margin is 76.40%, with operating margin of -4024.93%, and net profit margin of -1106.72%.
Gross Margin76.40%
Operating Margin-4024.93%
Pretax Margin-1092.36%
Net Profit Margin-1106.72%
EBITDA Margin-3982.39%
EBIT Margin-4024.93%
Analyst Forecast
The average price target for Aligos Therapeutics is $39.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$39.33
Price Target Upside490.54% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-55.88%
EPS Growth Forecast6.14%